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ABSTRACT 
Dasatinib, a second generation multi-target tyrosine kinase inhibitor (TKI) is active against many imatinib-resistant BCR-ABL 
mutant forms, Src, and c-Kit tyrosine kinases. While skin hypopigmentation is a well recognized adverse effect of first 
generation TKIs; it has rarely been reported with dasatinib. We report a rare case of diffuse cutaneous hypopigmentation and 
bilateral supercilliary madarosis induced by dasatinib. A 51 year-old Indian male with no co-morbidities and with history of 
chronic myelogenous leukaemia with complex variant of Philadelphia translocation and E 225 V mutation in P loop domain of 
bcr-abl transcript who was initiated on imatinib followed by dasatinib as a part of treatment. After 5 months of treatment with 
dasatinib, he developed supercilliary madarosis bilaterally. Cutaneous side effects may adversely affect patient’s quality of life 
and, therefore, require prompt attention to prevent long-term complications or suboptimal outcomes due to poor compliance. 
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ith tyrosine kinase inhibitors being 
increasingly used for the treatment of various 
malignancies, it is important for physicians to 
become familiar with the adverse effects of these 
chemotherapeutic agents. Tyrosine kinase inhibition 
through blockade of the c-Kit/SCF signal transduction 
pathway likely plays a key role in dasatinib-induced 
cutaneous pigmentary changes. The paradoxical ability of 
tyrosine kinase inhibitors (TKIs) such as imatinib and 
dasatinib to result in both hypo- and/or hyper 
pigmentation, especially in same patient, remains unclear. 
In comparison with the previous standards of care, TKI 
benefits include more rapid response rate, increased 
survival, and fewer side effects. The improved long-term 
outcomes have altered the approach to CML management 
from a progressive fatal disease with a poor prognosis to a 
chronic condition. 
 
Prolonged survival increases the need for patient 
education, support, monitoring, and assistance. Further 
research is needed to elucidate potential genetic 
mechanisms responsible for cutaneous pigmentary changes 
and the interference caused by TKIs, and may greatly 
contribute to understanding and potentially treating a 
variety of pigmentation disorders including melanomas. 
Moreover, the incidence of many cutaneous reactions 
appears to be related to the cumulative dosage, which 
further supports a specific pharmacological effect of the 
drug rather than immunologic or allergic mechanisms. 
Many of these specific cutaneous toxicities may be 
regarded as potential indicators of responsiveness to 
therapy, or even direct markers of treatment outcome, 
because they indicate biological activity. Cutaneous side 
effects may adversely affect patients’ quality of life and, 
therefore, require prompt attention to prevent long-term 
complications or suboptimal outcomes due to poor 
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compliance. Anecdotal case reports together with profound 
clinical trials can optimize regular monitoring and 
management of treatment-related side effects providing 
better therapy adherence and outcome. 
CASE REPORT 
A 51 year old male patient, known case of chronic 
myelogenous leukaemia on treatment with dasatinib, non 
smoker, non alcoholic and vegetarian by diet was referred 
to our department. Patient has developed bilateral 
supercilliary madarosis (Fig. 1) for the past 18 months. On 
examination, the patient was conscious, well oriented, well 
built with stable vitals. There was no pallor, icterus, 
cyanosis, clubbing, pedal oedema or lymphadenopathy. 
Supercialliary madarosis was evident bilaterally. His 
systemic examination was unremarkable. Patient is on 
Dasatinib 70mg OD and regular follow-up. 
He was apparently well 10 years ago when he 
developed dry cough and breathlessness, both of which 
started 15 days prior to the first hospital visit. Cough was 
non-productive, with no associated fever, haemoptysis or 
cervical lymphadenopathy. There were no associated 
diurnal or postural variations. Breathlessness was modified 
Medical Research Council dyspnoea scale grade II. Both 
the cough and breathlessness were increased on exertion 
and were partly relieved on medication.  
 
Figure 1 - Front, right and left lateral profile of patient 
showing supercilliary madarosis 
His routine blood investigations on May, 2005 revealed 
haemoglobin - 12.5gm/dl, TLC – 188,400/mm3, DLC - N38 
L2E2M0B2 with myeloblasts (1%), promyelocytes (3%), 
myelocytes (15%), metamyelocytes (17%) and band forms 
(20%). Blood picture revealed normocytic normochromic 
RBCs with 56% immature cells of myeloid series. Bone 
marrow aspiration showed increased megakaryocytes, 
myeloid hyperplasia with predominance of segmented 
cells, eosinophils and basophils with blasts <5%, thereby 
diagnosing the patient as a case of CML. Quantitative bcr-
abl translocation assay revealed transcript ratio of 91%. 
In May 2005, patient was started on tablet imatinib 
mesylate 400 mg OD. On repeat fluorescence in situ 
hybridization (FISH) assay, done three months after 
initiation on imatinib monotherapy, transcript ratio was 
0.53%. The transcript ratio on Quantitative bcr abl 
translocation assay ranged between 0-1% between 
September 2005 and November 2012. FISH for bcr-abl 
was positive on two occasions; it was 56% in September 
2006 (Fig. 2) and 11% in august 2007. 
 
Figure 2 - FISH analysis showing 56 fusion signals 
Philadelphia Signifying t (9;22) 
 
Figure 3 - Complex variant of Philadelphia Translocation 
In April 2011, the patient visited a psychiatrist with 
complaints of anxiety, anger, desire to hurt and self harm 
and he was initiated on sodium valproate 750mg OD, 
clonazepam 0.25mg HS and Resperidone 1mg HS. Patient 
defaulted on imatinib from December 2013 to April 2014. 
Patient underwent bone marrow biopsy in August 2014 
which revealed normal marrow components and reactive 
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lymphoid aggregates with no evidence of blasts. The 
chromosome analysis for hematologic malignancy 
revealed 46XY t (9;10;22) (q34, p11.2, q11.2) i.e. complex 
variant of Philadelphia translocation (Fig. 3). Quantitative 
bcr abl translocation assay revealed a transcript ratio of 
27.38%. Imatinib resistance mutation analysis (IRMA) via 
RTPCR from peripheral blood was also done which 
showed E225V mutation in P loop domain of bcr-abl 
transcript. 
Subsequently, patient was started on Dasatinib 100 mg 
OD on September 7, 2014 but stopped for 12 days 
(October 16, 2014 to October 28, 2014) following severe 
drug induced dermatitis and grade I haemorrhoids. It was 
restarted at a lower dose (50 mg OD) and then escalated to 
70 mg OD and is continued till date. 
DISCUSSION 
Tyrosine kinase inhibitors are used in treatment of various 
hematologic malignancies as well as solid organ tumours 
including soft tissue sarcomas. In 2001, the first TKI 
Imatinib was approved for the treatment of a malignancy, 
and much has been elucidated about its pharmacokinetics, 
pharmacodynamics, mechanism of action and adverse 
reactions including toxities. Dasatinib, a second-generation 
multi-target TKI is active against many imatinib-resistant 
bcr-abl mutant forms, Src, and c-Kit tyrosine kinases and 
platelet derived growth factor receptor b (PDGFR-b) 
tyrosine kinases [1]. Currently, dasatinib is FDA approved 
for treatment of CML, but is actively being investigated 
for other malignancies such as sarcoma. 
As mentioned above, various pigmentary abnormalities 
have been associated with imatinib. Reversible, dose-
related hypopigmentation is a well-recognized adverse 
effect. Histologically there is a reduction or complete 
absence of melanocytes in association with a partial or 
total loss of epidermal pigmentation. Superficial 
perivascular and perifollicular lymphocytic infiltrates are 
generally absent. In one series, 41% of patients treated 
with imatinib developed localized or generalized 
hypopigmentation, at a median of four weeks after 
initiating treatment. Paradoxical accelerated re-
pigmentation and hyper-pigmentation have also been 
described. In one prospective series, skin hyper 
pigmentation occurred in 3.6% of ethnically pigmented 
patients treated with imatinib [2]. The mechanism of 
paradoxical hyper pigmentation is unclear; however, the 
variable response to imatinib may depend upon specific c-
Kit mutation or interactions with other tyrosine kinase 
receptors, resulting in increased melanin synthesis [3].  
Several dermatologic toxicities have been associated 
with first generation TKIs such as urticaria, lichenoid 
reaction, psoriasis, and Stevens-Johnson syndrome [4]. 
Rarely does it lead to severe epidermal necrolysis, acute 
generalized exanthematous pustulosis, hyper pigmentation 
and lichenoid eruption, photo induced dermatoses, 
pseudoporphyria, pityriasiform/ psoriasiform eruptions, 
superficial oedema, neutrophilic dermatoses, 
panniculitides [5-6]. Conversely, dasatinib has very few 
cutaneous side effects, the most common being non-
specific maculopapular rashes and skin exfoliation and 
irritation [4]. A few cases of dasatinib-induced hair 
depigmentation have been reported [7,8]. 
However, skin pigment changes associated with 
dasatinib have only been reported once in a paediatric 
leukemic patient who developed achromic patches on neck 
and dorsal surface of hands, and complete depigmentation 
of hair, eyelashes and eyebrows [7]. The case described 
here is noteworthy; as this is the first description of 
dasatinib-induced supercilliary madarosis which 
emphasizes role of c-Kit pathway in melanocyte biology. 
The proto-oncogene c-Kit is a gene encoding class III 
tyrosine kinase receptor, while stem cell factor (SCF) is 
the ligand for c-Kit. SCF and c-kit interaction plays an 
important role in the development of hematopoietic stem 
cells, germ cells, mast cells and melanocytes [9]. In 
particular, SCF is responsible for the permanent survival, 
proliferation and migration functions in c-Kit receptor-
expressing melanocytes, and therefore, plays a critical role 
in the development of melanocytes from their precursors in 
the embryonic neural crest cells during embryogenesis and 
maintenance of melanocyte lineage in adult skin [9]. 
Inhibition of c-Kit by TKIs is thought to be responsible for 
hypopigmentation. It is also known that mutations in the c-
Kit gene are associated with skin and hair 
hypopigmentation syndromes, such as piebaldism 
(autosomal dominant disorder of melanocyte development 
characterized by white hair and congenital amelanotic 
patches on forehead, torso and extremities) [10]. 
In addition, several in vitro and in vivo studies also 
support the association of c-Kit and its downstream 
pathway in normal integument pigmentation. For example, 
imatinib significantly decreases the number of cells with 
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high tyrosine kinase activity in vitiligo and normal 
melanocytes, thereby inhibiting melanogenesis [11]. The 
various interactions between photosensitivity and 
molecular pathways involved in the response to ultraviolet 
stress can explain the different phenotype of pigmentary 
changes caused by TKIs. Pigmentation is associated with 
c-kit signalling and resultant activation of the tyrosine 
kinases involved in melanogenesis, such as tyrosinase and 
tyrosinase-related protein 1. 
Hemesath et al. suggested that the signal transmission 
downstream activation of the MAP kinase Erk-2, modulate 
the pigment production through an effect on the tyrosine 
pigmentation gene promoter and expression of genes, 
essential for melanocyte survival and development. The 
link between the c-kit receptor and melanogenic genes 
probably occurs through the microphtalmia transcription 
factor (MITF), which is crucial for melanocyte 
development [12]. 
The overlap of target receptors between imatinib and 
dasatinib likely explains the pigmentary changes seen with 
dasatinib in this patient. Also, as TKIs appear to interfere 
with molecular mechanisms involved in response to 
ultraviolet stress, chronic inhibition of c-Kit may impair 
the protective cutaneous response to ultraviolet light, 
which may lead to hyperpigmentation of sun-exposed 
areas [13]. As most cases of TKIs induced hypo-
pigmentation are dose dependent and reversible, return to 
baseline skin pigmentation is not surprising after 
discontinuation of TKIs. 
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